Sunnyvale, CA – October 20, 2015 – JSR Life Sciences announced today that it will release Amsphere™ A3, a next generation Protein A chromatography resin for advanced protein separation in downstream processing of therapeutic antibodies manufacturing at the IBC Life Sciences' BioProcess International Conference & Exposition in Boston, MA held Oct. 26-29, 2015. Amsphere™ A3 will be commercially available in January 2016.
Amsphere™ A3 is a high capacity resin with overall improved process robustness, flow characteristics, optimized impurity removal, productivity and resin lifetime.
JSR launched its first Protein A chromatography media in 2012 and has since focused on leveraging JSR Corporation's core competency in advanced polymer chemistry coupled with JSR Life Sciences' expertise in protein ligand design and conjugation. As a result, Amsphere™ A3 is uniquely designed to purify mAbs using an innovative polymer matrix and proprietary ligand technology.
"We believe that Amsphere™ A3 is in a position to redefine the standard for protein A resin and to provide customers with options," said Eric Johnson, President of JSR Micro, Inc. "It's shown great, competitive results across the board with beta testers, and we're eager and committed to developing solutions at that level for the bioprocessing industry."
JSR Life Sciences will exhibit at BioProcess International in booth 617 and will present additional data in a technology workshop on Wednesday, October 28 at 12:05 PM.
About JSR Life Sciences
JSR Life Sciences is a global company built on more than 50 years of polymer expertise and began research in the life sciences more than 30 years ago. Using a variety of integrated, leading-edge technologies, JSR Life Sciences provides materials that contribute to the manufacturing process of biopharmaceuticals, life science research applications, in vitro diagnostics and medical devices.